Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03661723 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT03661723: Completed Phase 2 study, sponsored by Dana-Farber Cancer Institute.
NCT03661723 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03661723, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This research study is studying pembrolizumab and re-irradiation as possible treatments for glioblastoma. The drugs involved in this study are: * Pembrolizumab * Radiation * Bevacizumab, an FDA-approved drug for treating recurrent glioblastoma multiforme (GBM)
Primary Outcome
Per Response Assessment in Neuro-Oncology (RANO) Criteria: * Complete Response (CR): * Disappearance of all enhancing measurable \& non-measurable disease sustained for at least 4 weeks * No new lesions * Stable or improved non-enhancing (T2/FLAIR) lesions * No corticosteroids (or physiologic replacement doses only) * And stable or improved clinically * Partial Response (PR): * \>=50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurab
Interventions
- DRUG Pembrolizumab
- DRUG Bevacizumab
- RADIATION Re-irradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2018-09-28 |
| Est. Completion | 2024-08-01 |
| Phase | Phase 2 |
What the finished NCT03661723 record still lists
NCT03661723 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03661723 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03661723 about?
NCT03661723 is a clinical study titled "Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma". This research study is studying pembrolizumab and re-irradiation as possible treatments for glioblastoma. The drugs involved in this study are: * Pembrolizumab * Radiation * Bevacizumab, an FDA-approved drug for treating recurrent glioblastoma multiforme (GBM)
What is the current status of trial NCT03661723?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2018-09-28. Estimated completion is 2024-08-01.
What interventions are being tested in trial NCT03661723?
The interventions under investigation include: Pembrolizumab (DRUG), Bevacizumab (DRUG), Re-irradiation (RADIATION).
Who is sponsoring clinical trial NCT03661723?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03661723's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI